Journal Article10.1097/00042737-200301000-00006
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Ikuya Miki,Nobuo Aoyama,Toshiyuki Sakai,Daisuke Shirasaka,Casmir Wambura,Shuji Maekawa,Kohei Kuroda,Takao Tamura,Tomoko Kita,Toshiyuki Sakaeda,Katsuhiko Okumura,Masato Kasuga +11 more
78
TL;DR: The key to successful eradication of H. pylori, using lansoprazole or rabeprazole with clarithromycin and amoxicillin, is clarithsromycin susceptibility, not CYP2C19 polymorphism.
read more
Abstract: Objective Helicobacter pylori treatment failure is thought to be due mainly to polymorphic cytochrome P450 2C19 (CPY2C19) genetic polymorphism, associated with proton pump inhibitor metabolism, and antimicrobial susceptibility. This report has ascertained which was more important, CPY2C19 polymorphism or antimicrobial susceptibility, when using 1-week lansoprazole-based or rabeprazole-based triple therapy in Japan. Design An open, randomized, parallel group study. Setting One hundred and forty-five subjects with H. pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week. Antimicrobial resistance testing was performed by E-test. More than 4 weeks after completion of treatment, H. pylori status was assessed by 13C-urea breath test, histology, and culture. Results Cure rates expressed as intention-to-treat and per-protocol analyses, respectively, were 79.6 and 83.0% with LAC, 85.4 and 89.1% with RAC20, and 83.3 and 88.9% with RAC40. In the case of clarithromycin-sensitive strains, the cure rates were more than 97%, regardless of CPY2C19 polymorphism. However, treatment succeeded in only one out of 16 clarithromycin-resistant strains. Conclusions The key to successful eradication of H. pylori, using lansoprazole or rabeprazole with clarithromycin and amoxicillin, is clarithromycin susceptibility, not CPY2C19 polymorphism.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
H pylori antibiotic resistance: prevalence, importance, and advances in testing
TL;DR: The aim was to review the prevalence of H pylori resistance to these various antibiotics, their clinical importance, and methods of testing, especially in light of the resistance mechanism which allows application of molecular methods.
1K
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.
Lori A. Fischbach,E. L. Evans +1 more
TL;DR: This data indicates that the presence of drug resistance in Helicobacter pylori infection results in down-regulation in the antiviral therapies used to treat the disease.
396
Review article: the treatment of refractory Helicobacter pylori infection.
F. Mégraud,H. Lamouliatte +1 more
TL;DR: It is important to choose antibiotics which do not face resistance problems and which increase the dosage of antisecretory drugs and the duration of treatment and, if possible, to add a topical agent such as bismuth salt when administering a new treatment.
253
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection
TL;DR: The decreasing efficacy of H. pylori eradication treatments over time makes the search for better regimens and adjuvant medications a priority.
198
CYP2C19 Polymorphism and Proton Pump Inhibitors
TL;DR: Limited data suggest that proton pump inhibitors-induced healing rates in gastro-oesophageal reflux disease are apparently higher in poor metabolizers/het extensive metabolizers than in extensive metabolites of CYP2C19, and initial genotyping for this enzyme and higher dosage in extensive metabolizer is likely to improve the clinical efficacy of proton pumps.
180
References
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
S. M. F. De Morais,G. R. Wilkinson,Joyce Blaisdell,K. Nakamura,Urs A. Meyer,Joyce A. Goldstein +5 more
TL;DR: It is reported that the principal defect in poor metabolizers is a single base pair (G-->A) mutation in exon 5 of CYP2C19, which creates an aberrant splice site that results in a truncated, non-functional protein.
982
•Journal Article
Identification of a new genetic defect responsible for the polymorphism of (s)-mephenytoin metabolism in japanese
S. M. F. De Morais,Grant R. Wilkinson,Joyce Blaisdell,Urs A. Meyer,K. Nakamura,Joyce A. Goldstein +5 more
TL;DR: A new mutation is identified in Japanese poor metabolizers, consisting of a guanine to adenine mutation at position 636 of exon 4 of CYP2C19, which creates a premature stop codon.
788
Factors influencing the eradication of Helicobacter pylori with triple therapy
David Y. Graham,David Y. Graham,Ginger M. Lew,Ginger M. Lew,Hoda M. Malaty,Hoda M. Malaty,Dolores G. Evans,Dolores G. Evans,Doyle J. Evans,Doyle J. Evans,Peter D. Klein,Peter D. Klein,Lesley C. Alpert,Lesley C. Alpert,Robert M. Genta,Robert M. Genta +15 more
TL;DR: It is concluded that triple therapy is effective for eradication of H. pylori and that future studies need to take compliance into account for comparisons between regimens.
610
Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.
Takashi Ishizaki,Y. Horai +1 more
TL;DR: The metabolism of rabeprazole is less dependent on CYP2C19 and therefore is the least affected by this genetic polymorphism and the therapeutic effectiveness of proton pump inhibitors during the treatment of acid‐related diseases.
459
A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates.
TL;DR: The overall eradication rates of currently advised Helicobacter pylori eradication regimens were determined and conflicting evidence on the impact of antimicrobial resistance on the eradications rates was resolved.
353